Enhanced MCP-1 release by keloid CD14+ cells augments fibroblast proliferation: Role of MCP-1 and Akt pathway in keloids

Experimental Dermatology

Volumn 19, Issue 8, 2010, Pages

  Liao, Wei Ting ^a   Yu, Hsin Su ^a   Arbiser, Jack L ^b   Hong, Chein Hui ^c   Govindarajan, Baskaran ^b   Chai, Chih Yin ^d   Shan, Wan Ju ^a   Lin, Yu Fen ^a   Chen, Gwo Shing ^a   Lee, Chih Hung ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Kaohsiung General Veterans Hospital   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Akt; Fibroblast proliferation; Keloid; MCP 1; Monocytes macrophages

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CD14 ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 2;

ADOLESCENT; ADULT; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG INHIBITION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; KELOID; MACROPHAGE; MALE; MONOCYTE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; ANTIGENS, CD14; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; COCULTURE TECHNIQUES; FEMALE; FIBROBLASTS; HUMANS; KELOID; MALE; MONOCYTES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CCR2; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 77954855838     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.01021.x     Document Type: Article

References (44)

1. Al-Attar A, Mess S, Thomassen J M, Kauffman C L, Davison S P. Keloid pathogenesis and treatment. Plast Reconstr Surg 2006, 117:286-300.
2. Smith J C, Boone B E, Opalenik S R, Williams S M, Russell S B. Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways. J Invest Dermatol 2008, 128:1298-1310.
3. Haisa M, Okochi H, Grotendorst G R. Elevated levels of PDGF alpha receptors in keloid fibroblasts contribute to an enhanced response to PDGF. J Invest Dermatol 1994, 103:560-563.
4. Liu W, Wang D R, Cao Y L. TGF-beta: a fibrotic factor in wound scarring and a potential target for anti-scarring gene therapy. Curr Gene Ther 2004, 4:123-136.
5. Yu H, Bock O, Bayat A, Ferguson M W, Mrowietz U. Decreased expression of inhibitory SMAD6 and SMAD7 in keloid scarring. Br J Plast Surg 2006, 59:221-229.
6. Campaner A B, Ferreira L M, Gragnani A, Bruder J M, Cusick J L, Morgan J R. Upregulation of TGF-beta1 expression may be necessary but is not sufficient for excessive scarring. J Invest Dermatol 2006, 126:1168-1176.
7. Ferreira A M, Takagawa S, Fresco R, Zhu X, Varga J, DiPietro L A. Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol 2006, 126:1900-1908.
8. Hartl D, Griese M, Nicolai T. A role for MCP-1/CCR2 in interstitial lung disease in children. Respir Res 2005, 6:93.
9. Okuma T, Terasaki Y, Kaikita K. C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. J Pathol 2004, 204:594-604.
10. Xia Y, Frangogiannis N G. MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy. Inflamm Allergy Drug Targets 2007, 6:101-107.
11. Tesch G H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008, 294:F697-F701.
12. Marra F. Renaming cytokines: MCP-1, major chemokine in pancreatitis. Gut 2005, 54:1679-1681.
13. Yoshimura T, Leonard E J. Secretion by human fibroblasts of monocyte chemoattractant protein-1, the product of gene JE. J Immunol 1990, 144:2377-2383.
14. Karrer S, Bosserhoff A K, Weiderer P. The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 2005, 124:92-98.
15. Carulli M T, Ong V H, Ponticos M. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005, 52:3772-3782.
16. Mizutani K, Roca H, Varsos Z, Pienta K J. Possible mechanism of CCL2-induced Akt activation in prostate cancer cells. Anticancer Res 2009, 29:3109-3113.
17. Wakelin S J, Forsythe J L, Garden O J, Howie S E. Commercially available recombinant sonic hedgehog up-regulates Ptc and modulates the cytokine and chemokine expression of human macrophages: an effect mediated by endotoxin contamination? Immunobiology 2008, 213:25-38.
18. Boyce D E, Ciampolini J, Ruge F, Murison M S, Harding K G. Inflammatory-cell subpopulations in keloid scars. Br J Plast Surg 2001, 54:511-516.
19. Tacke F, Randolph G J. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006, 211:609-618.
20. Abe R, Donnelly S C, Peng T, Bucala R, Metz C N. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001, 166:7556-7562.
21. Shegogue D, Trojanowska M. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 2004, 279:23166-23175.
22. Zhang Q, Kelly A P, Wang L. Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type i collagen expression in keloid fibroblasts via blocking PI-3K/Akt signaling pathways. J Invest Dermatol 2006, 126:2607-2613.
23. Sakai N, Wada T, Furuichi K. MCP-1/CCR2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes. J Leukoc Biol 2006, 79:555-563.
24. Xu Y X, Talati B R, Janakiraman N, Chapman R A, Gautam S C. Growth factors: production of monocyte chemotactic protein-1 (MCP-1/JE) by bone marrow stromal cells: effect on the migration and proliferation of hematopoietic progenitor cells. Hematology 1999, 4:345-356.
25. Hoogeveen R C, Morrison A, Boerwinkle E. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 2005, 183:301-307.
26. Gosling J, Slaymaker S, Gu L. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999, 103:773-778.
27. Lakos G, Takagawa S, Chen S J. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004, 165:203-217.
28. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003, 121:510-516.
29. Hayashidani S, Tsutsui H, Shiomi T. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2003, 108:2134-2140.
30. Gharaee-Kermani M, Denholm E M, Phan S H. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996, 271:17779-17784.
31. Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol 2000, 164:6174-6179.
32. Zickus C, Kunkel S L, Simpson K. Differential regulation of C-C chemokines during fibroblast-monocyte interactions: adhesion vs. inflammatory cytokine pathways. Mediators Inflamm 1998, 7:269-274.
33. Yamamoto T. Chemokines and chemokine receptors in scleroderma. Int Arch Allergy Immunol 2006, 140:345-356.
34. Yeh F L, Shen H D, Tai H Y. Decreased production of MCP-1 and MMP-2 by keloid-derived fibroblasts. Burns 2009, 35:348-351.
35. Lim C P, Phan T T, Lim I J, Cao X. Cytokine profiling and Stat3 phosphorylation in epithelial-mesenchymal interactions between keloid keratinocytes and fibroblasts. J Invest Dermatol 2009, 129:851-861.
36. Girardeau S, Mine S, Pageon H, Asselineau D. The Caucasian and African skin types differ morphologically and functionally in their dermal component. Exp Dermatol 2009, 18:704-711.
37. Hogaboam C M, Bone-Larson C L, Lipinski S. Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models. J Immunol 1999, 163:2193-2201.
38. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999, 117:159-165.
39. Yamamoto T, Eckes B, Hartmann K, Krieg T. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 2001, 26:133-139.
40. Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos J L. Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 2001, 44:1382-1386.
41. Yamamoto T, Eckes B, Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 2001, 31:2936-2941.
42. Kim A, DiCarlo J, Cohen C. Are keloids really " gli-loids" ?: High-level expression of gli-1 oncogene in keloids. J Am Acad Dermatol 2001, 45:707-711.
43. Ong C T, Khoo Y T, Mukhopadhyay A. mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Exp Dermatol 2007, 16:394-404.
44. Mukhopadhyay A, Khoo A, Cheong H H. Targeting of Sp1 transcription factor: a novel therapeutic approach for keloids, an in vitro analysis. Exp Dermatol 2007, 16:1023-1031.